Afficher la couverture 'Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series | Droitcourt, C' en grand format
/5

0 avis

Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series

Archive ouverte

Droitcourt, C | Adamski, Henri | Polat, A | Polard, E | Kerjouan, M | Arnouat, B | Le Garrec, M | Oger, E | Dupuy, A | Jouneau, S

Edité par CCSD ; Wiley -

International audience. The oral antifibrotic agent, pirfenidone (PFD), 5-methyl-l-phenyl-[1H]-pyridine, is used to treat idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. In trials, PFD reduces disease progression and decreases mortality. The most common adverse events of PFD are skin manifestations (25%), described as photosensitivity or rash, but they are not well characterized. The objective of the present real-life study was to address the question of skin manifestations in patients treated with PFD for IPF.

Suggestions

Du même auteur

Pneumopathie d’hypersensibilité révélée par un syndrome de détresse respiratoire aiguë

Archive ouverte | Arnouat, B | CCSD

National audience

Concordance of severity scores assessed on photographs in Hidradenitis suppurativa

Archive ouverte | Prouteau, C | CCSD

International audience

Factors associated with early relapse of infantile haemangioma in children treated for at least six months with oral propranolol: A case-control study using the 2014-2021 French Ouest DataHub

Archive ouverte | Mauguen, C | CCSD

International audience. BACKGROUND: The factors associated with early relapse of infantile haemangioma (IH) after a first course of treatment with oral propranolol for at least six months (initiated after the market...

Chargement des enrichissements...